In This Article:
As the European Central Bank's recent rate cuts spark optimism and Germany's DAX index sees a notable rise, the spotlight turns to small-cap stocks that might be overlooked in broader market discussions. In this favorable environment, identifying stocks with robust foundations becomes crucial for potential long-term gains.
Top 10 Undiscovered Gems With Strong Fundamentals In Germany
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Mineralbrunnen Überkingen-Teinach GmbH KGaA | 19.91% | 0.96% | -5.02% | ★★★★★★ |
| Westag | NA | -1.56% | -21.68% | ★★★★★★ |
| FRoSTA | 8.18% | 4.36% | 16.00% | ★★★★★★ |
| EnviTec Biogas | 37.96% | 19.34% | 51.22% | ★★★★★★ |
| Mühlbauer Holding | NA | 10.49% | -12.73% | ★★★★★★ |
| Südwestdeutsche Salzwerke | 0.30% | 4.57% | 25.01% | ★★★★★☆ |
| HOMAG Group | NA | -31.14% | 23.43% | ★★★★★☆ |
| Baader Bank | 91.28% | 12.42% | -8.00% | ★★★★★☆ |
| Wilson | 64.79% | 30.09% | 68.29% | ★★★★☆☆ |
| BAUER | 78.29% | 2.30% | -38.28% | ★★★★☆☆ |
Here's a peek at a few of the choices from the screener.
M1 Kliniken
Simply Wall St Value Rating: ★★★★★☆
Overview: M1 Kliniken AG, with a market cap of €332.14 million, operates in the field of aesthetic medicine and plastic surgery services across Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia.
Operations: M1 Kliniken AG generates revenue primarily from its Trade segment (€251.09 million) and Beauty segment (€82.23 million).
M1 Kliniken's earnings soared 163.7% over the past year, far outpacing the Healthcare industry's 30.9%. Recent half-year sales hit €167.74 million, up from €150.79 million last year, while net income jumped to €9.9 million from €3.42 million. The company repurchased shares in 2024 and trades at 66% below its estimated fair value, suggesting potential undervaluation despite a volatile share price recently and an increased debt-to-equity ratio of 8.5%.
-
Take a closer look at M1 Kliniken's potential here in our health report.
-
Review our historical performance report to gain insights into M1 Kliniken's's past performance.
PharmaSGP Holding
Simply Wall St Value Rating: ★★★★★☆
Overview: PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany, with a market cap of €256.59 million.
Operations: PharmaSGP Holding SE generates revenue primarily from its pharmaceutical segment, which reported €107.29 million.
PharmaSGP Holding, a small player in the pharmaceutical sector, has seen its earnings grow by 38.1% over the past year, outpacing the industry average of 1.5%. Trading at 80.3% below its estimated fair value, PSG's high-quality earnings and strong EBIT coverage of interest payments (7.4x) make it an intriguing prospect. Despite a net debt to equity ratio of 60.3%, which is considered high, recent share repurchases indicate confidence from within the company